Mukonzo, Jackson K.Röshammar, DanielWaako, PaulAndersson, MariaFukasawa, TakashiMilani, LiliSvensson, Jan OlofOgwal-Okeng, JasperGustafsson, Lars L.Aklillu, Eleni2021-12-122021-12-122009Mukonzo, JK (2009). Rö shammar D, Waako P, Andersson M, Fukasawa T, Milani L, et al. A novel polymorphism in ABCB1 gene, CYP2B646 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. British journal of clinical pharmacology , 68 (5), 690-9.10.1111/j.1365-2125.2009.03516.xhttps://nru.uncst.go.ug/xmlui/handle/123456789/339Efavirenz, a potent antiretroviral agent, is the cornerstone of highly active antiretroviral therapy (HAART), particularly in human immunodeficiency virus (HIV) and tuberculosis co-infected patients being co-treated with rifampicin. Its essential role as an affordable HAART treatment in resource-poor countries is due to its relatively low cost, manageable pill burden and solid efficacy as well as safety documentationenABCB1CYP2B6CYP3A5EfavirenzPopulation pharmacokineticsUgandansArticle